Shockwave medical, inc. (SWAV)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Revenue:
Product revenue

15,197

14,313

11,333

10,012

7,269

5,062

3,600

2,279

1,322

Cost of revenue:
Cost of product revenue

5,651

5,553

4,401

4,133

3,072

3,304

1,973

1,179

794

Gross profit

9,546

-

-

-

4,197

-

-

-

-

Operating expenses:
Research and development

11,890

10,075

8,368

6,926

7,484

6,119

5,533

5,530

5,516

Sales and marketing

10,411

9,596

8,192

6,961

5,871

4,925

4,801

4,372

3,438

General and administrative

6,224

4,451

3,437

3,245

3,001

1,842

1,369

1,392

1,376

Total operating expenses

28,525

32,747

24,398

21,265

16,356

16,190

13,676

12,473

11,124

Loss from operations

-18,979

-15,362

-13,065

-11,253

-12,159

-11,128

-10,076

-10,194

-9,802

Interest expense

277

198

251

250

245

185

158

40

18

Change in fair value of warrant liability

-

0

0

0

609

-1

104

-10

-41

Other income, net

504

826

385

913

221

100

166

138

185

Net loss before taxes

-18,752

-14,734

-12,931

-10,590

-12,792

-11,212

-10,172

-10,086

-9,594

Income tax provision

23

11

26

18

7

-

6

21

-

Net loss

-18,775

-14,745

-12,957

-10,608

-12,799

-11,223

-10,178

-10,107

-9,594

Unrealized gain on available-for-sale securities

68

-

-18

75

-

0

0

0

1

Total comprehensive loss

-18,707

-14,767

-12,975

-10,533

-12,799

-11,223

-10,178

-10,107

-9,593

Net loss per share, basic and diluted

-0.59

0.07

-0.46

-0.38

-1.37

-6.24

-5.73

-5.79

-5.63

Shares used in computing net loss per share, basic and diluted

31,644

30,165

28,085

28,002

9,364

1,801

1,776

1,745

1,705